Cargando…

Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma

SIMPLE SUMMARY: We measured serum thyroglobulin (Tg), a marker of thyroid cancer metastases, in patients operated on with total thyroidectomy for thyroid carcinoma on three different occasions at the beginning of follow-up: 30 days before radioactive iodine therapy (RAI) for remnant ablation (and at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Signore, Alberto, Lauri, Chiara, Di Paolo, Arianna, Stati, Valeria, Santolamazza, Giuliano, Capriotti, Gabriela, Prosperi, Daniela, Tofani, Anna, Valabrega, Stefano, Campagna, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251887/ https://www.ncbi.nlm.nih.gov/pubmed/37296937 http://dx.doi.org/10.3390/cancers15112976

Ejemplares similares

Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis
por: Wang, Chen, et al.
Publicado: (2017)

Comparing the efficacy of thyroglobulin and thyroglobulin/ thyroid-stimulating hormone ratio models in predicting a successful response to radioactive iodine therapy
por: Ju, Yanli, et al.
Publicado: (2023)

Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer
por: Bandeira, Leonardo, et al.
Publicado: (2017)

Preablative Stimulated Thyroglobulin and Thyroglobulin Reduction Index as Decision-Making Markers for Second Radioactive Iodine Therapy in Patients with Structural Incomplete Response
por: Wang, Lihua, et al.
Publicado: (2021)

RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma
por: RUAN, MAOMEI, et al.
Publicado: (2013)

Lung Metastases From Papillary Thyroid Cancer With Persistently Negative Thyroglobulin and Elevated Thyroglobulin Antibody Levels During Radioactive Iodine Treatment and Follow-Up: Long-Term Outcomes and Prognostic Indicators
por: Qiu, Zhong-Ling, et al.
Publicado: (2020)

Risk factors associated with high thyroglobulin level following radioactive iodine ablation, measured 12 months after treatment for papillary thyroid carcinoma
por: Kim, Eun Young, et al.
Publicado: (2017)

The structure of natively iodinated bovine thyroglobulin
por: Kim, Kookjoo, et al.
Publicado: (2021)

Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients’ Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial
por: Jammah, Anwar A., et al.
Publicado: (2021)

Preradioactive Iodine Thyroglobulin Levels as Predictors of Metastasis in Well-Differentiated Thyroid Carcinoma Patients
por: Darmawan, Budi, et al.
Publicado: (2022)

Thyroglobulin Value Predict Iodine-123 Imaging Result in Differentiated Thyroid Cancer Patients
por: Campennì, Alfredo, et al.
Publicado: (2023)

Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer
por: Mu, Zhuan-Zhuan, et al.
Publicado: (2019)

Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
por: Fullmer, Tanner, et al.
Publicado: (2021)

Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
por: Werner, R. A., et al.
Publicado: (2016)

Low Iodine Diet for Preparation for Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma in Korea
por: Chung, Jae Hoon
Publicado: (2013)

Radioactive Iodine Therapy Decreases Recurrence in Thyroid Papillary Microcarcinoma
por: Creach, Kimberly M., et al.
Publicado: (2012)

Radioactive Iodine Therapy of Differentiated Thyroid Carcinoma: Redesigning the Paradigm
por: Goldsmith, Stanley J.
Publicado: (2017)

Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
por: Liu, Jierui, et al.
Publicado: (2019)

Radioactive Iodine Resistant Papillary Thyroid Cancer “Redifferentiated” With Dabrafenib
por: Zayouna, Christine, et al.
Publicado: (2021)

Radioactive iodine in low- to intermediate-risk papillary thyroid cancer
por: Zhao, Hengqiang, et al.
Publicado: (2022)

Exploration of thyroglobulin as a biomarker of iodine status in iodine-sufficient and mildly iodine-deficient pregnant women
por: Dineva, Mariana, et al.
Publicado: (2023)

Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer
por: Jo, Kwanhoon, et al.
Publicado: (2018)

Present status and future trends in molecular imaging of lymphocytes
por: Lauri, Chiara, et al.
Publicado: (2023)

Identification of Intermediate- to High-Risk Papillary Thyroid Carcinoma Patients Who May Be Safely Managed without the Performance of Delayed Stimulated Thyroglobulin Measurements following Total Thyroidectomy and Radioactive Iodine Therapy
por: Kim, Kyung-Hee, et al.
Publicado: (2015)

Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma
por: Murayama, Daisuke, et al.
Publicado: (2021)

Comparison of the Carcinogenic Effect of X-Irradiation with Radioactive Iodine on the Rat's Thyroid
por: Doniach, I.
Publicado: (1957)

Effects of Radioactive Iodine on the Rat Thyroid's Function, Regeneration and Response to Goitrogens
por: Doniach, I., et al.
Publicado: (1955)

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
por: McFarland, Daniel C, et al.
Publicado: (2014)

Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease
por: Kim, Sun Hwa, et al.
Publicado: (2013)

Sarcoidosis mimicking metastatic thyroid cancer following radioactive iodine therapy
por: Myint, Zin W., et al.
Publicado: (2015)

Thyroid Storm and Complete Heart Block after Treatment with Radioactive Iodine
por: Vennard, Kaitlyn, et al.
Publicado: (2018)

Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of  Differentiated Thyroid Cancer
por: Slonimsky, Einat, et al.
Publicado: (2020)

The Genomic Landscape of Radioactive Iodine Refractory and Avid Papillary Thyroid Carcinomas
por: Al-Kuraya, Khawla Sami, et al.
Publicado: (2021)

Reduction of thyroid radioactive iodine exposure by oral administration of cyclic oligosaccharides
por: Nishi, Kodai, et al.
Publicado: (2023)

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
por: Schmidt, Angelica, et al.
Publicado: (2017)

Cancer Rate of the Indeterminate Lesions at Low or High Risk According to Italian System for Reporting of Thyroid FNA
por: Valabrega, Stefano, et al.
Publicado: (2018)

Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves' Disease
por: Park, Se Hee, et al.
Publicado: (2017)

The utility of low-iodine diet in preparation for thyroid cancer therapy with radioactive iodine—A cohort study
por: Luo, Hongxiu, et al.
Publicado: (2022)

SAT520 Efficacy of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers
por: Toro-Tobon, David, et al.
Publicado: (2023)

Reflection of Dietary Iodine in the 24 h Urinary Iodine Concentration, Serum Iodine and Thyroglobulin as Biomarkers of Iodine Status: A Pilot Study
por: Hlucny, Katelyn, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lf2sr95a5cj9j5bqhbgdq1np24